Consequently, targeting the VEGF pathway has become a cornerstone of cancer therapy, with various anti-VEGF drugs approved for clinical use, such as the monoclonal antibody type Bevacizumab, Ramucirumab, and Ranibizumab or the recombinant fusion proteins like Aflibercept and Ziv-aflibercept. Here, VEGFA is linked to cancer.